Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

26.29 +1.93 (+7.90%)
Streaming Delayed Price Updated: 10:51 AM EDT, Jul 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Why Is AbbVie Stock Trading Higher On Thursday?
AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data. 
Via Benzinga
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda's looming patent loss. 
Via Benzinga
Topics Intellectual Property
NIKE, Datadog And Snap Are Among Top 11 Large Cap Gainers Last Week (June 30-July 4): Are The Others In Your Portfolio?
11 best performing large-cap stocks last week, including Symbotic, Nike, First Solar, Datadog, HPE, Summit Therapeutics, Carnival, POSCO, Wynn Resorts, SharkNinja, and Snap 
Via Benzinga
2 Soaring Stocks With More Upside Potential to Buy and Hold
Via The Motley Fool
Why AstraZeneca Stock Got Thumped on Thursday
Via The Motley Fool
Why Summit Therapeutics Stock Soared 8% Higher Today
Via The Motley Fool
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment
Via Benzinga
AstraZeneca In Talks To License Summit Therapeutics’ Experimental Lung Cancer Drug: Report
While the terms of the partnership agreement are still being negotiated, it could include an upfront payment worth several billion dollars and milestone payments, Bloomberg reported, while noting that... 
Via Stocktwits
2 Dividend Stocks to Buy and Never Sell
Via The Motley Fool
Topics Lawsuit
Why Summit Therapeutics Stock Tanked Today
Via The Motley Fool
This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Why Casey's General Stores Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
2 Soaring Stocks Wth More Upside Potential
Via The Motley Fool
3 No-Brainer Healthcare Stocks to Buy in June
Via The Motley Fool
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?
Via The Motley Fool
Temu Parent PDD, Regeneron Pharmaceutical And Burlington Stores Are Among Top 11 Large-Cap Losers Last Week (May 26-May 30): Are The Others In Your Portfolio?
11 large-cap stocks with worst performance in last week: SMMT, PDD, REGN, BAH, OKTA, DECK, CPRT, COO, TPL, HPQ, BURL. Mixed results, lowered forecasts. 
Via Benzinga
Which stocks are experiencing notable movement on Friday?
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Dow Edges Higher; Dell Shares Fall After Q1 Results
Via Benzinga
Topics Stocks
Why Summit Therapeutics Plunged Today
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Top movers in Friday's session
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
Summit Therapeutics Stock Tumbles On Oncology Drug Trial Data, Retail Flags ‘Insane’ Valuation
Summit now intends to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration seeking approval for Ivonescimab plus chemotherapy based on the results of the trial. 
Via Stocktwits
Topics Lawsuit Regulatory Compliance
Traders are paying attention to the gapping stocks in Friday's session.
Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure
There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival. 
Via Investor's Business Daily
Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint
Summit Therapeutics' Phase 3 trial met the primary goal in lung cancer, showing significant PFS benefit with ivonescimab plus chemotherapy. 
Via Benzinga
3 High-Flying Stocks That Could Soar Even More
Via The Motley Fool
Treasury Yields Top 5%: These 20 Stocks Tanked In Just One Hour
The selloff came as investors repriced risk across equities amid fears of persistently higher rates, sparked by soft demand at the 20-year Treasury auction. 
Via Benzinga
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
Topics Economy Law Enforcement
Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money
Via The Motley Fool
Topics Artificial Intelligence
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?
The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio? 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.